NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Current Portion of Long-Term Debt
NAYA Biosciences Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Current Portion of Long-Term Debt
$837.2k
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Current Portion of Long-Term Debt
$1.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
21%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Current Portion of Long-Term Debt
$1.7B
|
CAGR 3-Years
85%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Stryker Corp
NYSE:SYK
|
Current Portion of Long-Term Debt
$1.4B
|
CAGR 3-Years
486%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Current Portion of Long-Term Debt
$1.5B
|
CAGR 3-Years
26%
|
CAGR 5-Years
3%
|
CAGR 10-Years
39%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
837.2k
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Current Portion of Long-Term Debt amounts to 837.2k USD.
What is NAYA Biosciences Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
35%
Over the last year, the Current Portion of Long-Term Debt growth was 2%. The average annual Current Portion of Long-Term Debt growth rates for NAYA Biosciences Inc have been 35% over the past three years .
You don't have any saved screeners yet